NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1804.90 28.10 (1.58%)

1.2M NSE+BSE Volume

NSE 26 Nov, 2025 3:47 PM (IST)

433,056

Market Cap

Market Leader

0.7

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

23 May 2025

1804.90

1.58%

Sun Pharmaceutical Industries (SUNP IN) Q4FY25 Result Update ...

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Sun Pharma (SUNP) Q4FY25 EBIDTA (+11% YoY) was largely in line however moderate growth (9% YoY) in specialty sales after several quarters of strong double-digit growth was below our estimate. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...

Sun Pharmaceutical I.. has an average target of 1921.38 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

23 May 2025

1804.90

1.58%

India/EM outperformers; US/ROW underperformers

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharmaceutical Industries (SUNP) delivered 4%/9%/4% miss on revenue/EBITDA/PAT for 4QFY25. Lower-than-expected sales in global specialty and ROW led to a miss on 4QFY25 performance.

Number of FII/FPI investors decreased from 1326 to 1225 in Sep 2025 qtr

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1804.90

1.58%

Order vacating injunction on Leqselvi a material positive

Buy: Sun Pharmaceutical Industr...

Emkay

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharmaceutical Industries Ltd.

11 Mar 2025

1804.90

1.58%

On a spree to expand specialty portfolio

Buy: Sun Pharmaceutical Industr...

Recommendation Target

ICICI Securities Limited

Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones.

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharmaceutical Industries Ltd.

10 Mar 2025

1804.90

1.58%

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Buy: Sun Pharmaceutical Industr...

BOB Capital Markets Ltd.

SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharmaceutical Industries Ltd.

01 Feb 2025

1804.90

1.58%

Sun Pharma (BUY): Strong performance to continue

Buy: Sun Pharmaceutical Industr...

Recommendation Target

BOB Capital Markets Ltd.

Domestic sales grew by 14% in Q3FY25 driven partially by volume/new launches and price hikes. Strong domestic sales growth to continue

Sun Pharmaceutical I.. has an average target of 1921.38 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

21 Jan 2025

1804.90

1.58%

Addressing the oral IL-23 antagonist challenge to Ilumya

Buy: Sun Pharmaceutical Industr...

Target

Emkay

J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist peptide (Icotrokinra) could potentially compete with existing oral as well as injectable treatment options for moderate to severe plaque psoriasis.

Sun Pharmaceutical I.. has an average target of 1921.38 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

29 Oct 2024

1804.90

1.58%

Sun Pharma

Buy: Sun Pharmaceutical Industr...

Recommendation Target

ICICI Direct

Sun Pharmaceutical Industries Ltd. is trading above all available SMAs

Sun Pharmaceutical Industries Ltd.

29 Oct 2024

1804.90

1.58%

Sun Pharma (HOLD): All positives built into current valuations

Hold: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

SUNP reported 11% domestic sales growth led by 5% volume growth from ~14,000 MRs; leads in Rx count across 13 doctor categories

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharmaceutical Industries Ltd.

28 Oct 2024

1804.90

1.58%

Company surpasses expectations across multiple metrics

Buy: Sun Pharmaceutical Industr...

Target

Sharekhan

Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan.

Deven Choksey released a Accumulate report for Sun Pharmaceutical Industries Ltd. with a price target of 1853.0 on 07 Nov, 2025.

Is Sun Pharmaceutical Industries Ltd. worth buying?

1594 Votes:

Buy 75.41%

Sell 15.68%

Hold 8.91%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf